4//SEC Filing
TPAV, LLC 4
Accession 0001104659-25-006407
CIK 0001130598other
Filed
Jan 26, 7:00 PM ET
Accepted
Jan 27, 7:01 PM ET
Size
9.0 KB
Accession
0001104659-25-006407
Insider Transaction Report
Form 4
TPAV, LLC
10% Owner
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-29+96,348→ 96,348 totalExercise: $0.01→ Common Stock (96,348 underlying) - Purchase
Series A Warrant (right to buy)
2024-12-29+96,348→ 96,348 totalExercise: $13.42→ Common Stock (96,348 underlying)
Footnotes (5)
- [F1]The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.
- [F2]The Pre-Funded Warrants do not expire.
- [F3]The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.
- [F4]The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.
- [F5]The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.
Documents
Issuer
Traws Pharma, Inc.
CIK 0001130598
Entity typeother
IncorporatedNV
Related Parties
1- filerCIK 0002017798
Filing Metadata
- Form type
- 4
- Filed
- Jan 26, 7:00 PM ET
- Accepted
- Jan 27, 7:01 PM ET
- Size
- 9.0 KB